Eli Lilly Expands AI Drug Deal with Insilico for $2.75B

Eli Lilly and Insilico Medicine have expanded their partnership with a deal potentially worth $2.75 billion, focusing on the development of oral treatments through AI-powered drug discovery. The agreement grants Eli Lilly exclusive worldwide rights to develop, manufacture, and commercialize certain preclinical drugs generated using Insilico's proprietary AI engine.

The collaboration includes an initial payment of $115 million to Insilico Medicine, with additional payments contingent on achieving regulatory and commercial milestones. The company will also receive tiered royalties from future sales of these drugs. According to CNBC, the deal includes exclusive rights for Lilly to sell a GLP-1 drug for diabetes discovered by Insilico.

This partnership builds upon a research agreement signed between the companies in November 2023, which broadened their initial collaboration that began with an AI-based software licensing agreement. The new deal underscores the growing trend of pharmaceutical companies leveraging artificial intelligence to accelerate drug discovery and reduce reliance on animal testing.

Insilico Medicine has developed at least 28 drugs using its generative AI tools, with nearly half already in clinical stages, as reported by CNBC. The company went public in Hong Kong last December. This partnership aims to explore novel mechanisms and expedite the identification of promising therapeutic candidates across multiple disease areas.

The expanded collaboration comes amid a competitive landscape in AI-driven drug discovery, highlighting the increasing investment in this transformative technology within the pharmaceutical industry.